Citigroup Inc Novo Cure LTD Put Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Aug 10, 2023	BUY	$40.29 - $82.51 $2.8 Million - $5.73 Million	69,500 Added 1085.94%	75,900 $3.15 Million
Q1 2023 May 11, 2023	SELL	$56.44 - $118.81 $8.47 Million - $17.8 Million	-150,000 Reduced 95.91%	6,400 $384,000
Q4 2022 Feb 09, 2023	SELL	$63.98 - $85.37 $2.79 Million - $3.72 Million	-43,600 Reduced 21.8%	156,400 $11.5 Million
Q3 2022 Nov 10, 2022	BUY	$67.99 - $89.57 $3.4 Million - $4.48 Million	50,000 Added 33.33%	200,000 $15.2 Million
Q1 2022 May 12, 2022	SELL	$60.15 - $84.52 $13.8 Million - $19.4 Million	-230,000 Reduced 60.53%	150,000 $12.4 Million
Q4 2021 Feb 10, 2022	BUY	$75.08 - $121.99 $375,400 - $609,950	5,000 Added 1.33%	380,000 $28.5 Million
Q3 2021 Nov 10, 2021	BUY	$116.17 - $194.55 $43.6 Million - $73 Million	375,000 New	375,000 $43.6 Million

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.79B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.